Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

Presentation ESC 2024

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Presenter: David Erlinge

September 02, 2024

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ESC 2023

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Michael O'Riordan

August 26, 2023

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Conference News ESC 2021

FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2

Michael O'Riordan

August 29, 2021

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

Advertisement

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content